Mesothelioma Legal News

Rosetta Genomics Reports First Payment From the UK’s National Health …

The accurate identification of the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary is important in guiding clinician treatment decision John Bridgewater, M.D., University College London Hospital, UCL…

Rosetta Genomics Announces Sponsored Research Agreement With Ramot at Tel Aviv University

Joint Development of Nano-Carrier Delivery System for miR Mimetic Technology to Treat Cancer to Be Partially Funded by Israel’s Office of the Chief Scientist Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based molecular diagnosti…